CSGALNACT2

Across TCGA pan-cancer cohorts, CSGALNACT2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CSGALNACT2 data layer compared with 29 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher CSGALNACT2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CSGALNACT2 expression acts as an unfavorable survival marker, although some lineages such as BLCA and UCEC show a favorable association.

ESCA, BRCA, and BLCA are the cancer types where CSGALNACT2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	All	0.153	0.704	<.001	18	view →
BRCA	OS	Median	III,IV	0.313	0.834	.004	14	view →
BLCA	OS	Median	II,III,IV	0.885	0.407	.036	4	view →
UCEC	DFS	Median	All	0.950	0.623	.046	4	view →
LUSC	OS	Median	II,III,IV	0.173	0.677	.029	3	view →
SKCM	OS	Median	III,IV	0.245	0.721	.018	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CSGALNACT2–ESCA (OS)

Open the ESCA breakdown →